Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBT2D2)

Drug Name
AZD8233 Drug Info
Synonyms ION449
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Hypercholesterolaemia 5C80.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMBT2D2

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PCSK9 messenger RNA (PCSK9 mRNA) TTNIZ2B PCSK9_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cardiovascular disease
ICD Disease Classification BA00-BE2Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PCSK9 messenger RNA (PCSK9 mRNA) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04964557) A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia. U.S.National Institutes of Health.
2 AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844.